BioAdaptives, Inc. (BDPT) announced results of the recently completed in vivo trial showing the efficacy of its PrimiCell® product on muscle repair.
In the study mice were put into groups, PrimiCell® and the control group. The PrimiCell® group was given PrimiCell® for seven days prior to the treatment. Both groups were injected with cardiotoxin in the leg to cause muscle damage. At day one after the injection, day five, and day seven, test subjects from each group were analyzed to determine lesion size, inflammation, necrosis, and overall improvement. Results on day seven showed the PrimiCell® group had overall improvement greater than 56% better than the control group. The results are shown in the graph below.
BioAdaptives, Inc. Chairman and CEO, Barry Epling said, "The results partially explain the dramatic improvement we are seeing with PrimiCell® in humans and with animals using Equine Regen™ and Canine Regen™ which are the targeted animal formulations derived from the research and clinical trials completed on PrimiCell®."
Epling further stated, "BioAdaptives remains committed to further studies and observations of humans, performance horses, and companion animals."
The efficacy of the Mediterranean diet on health outcomes in adults with cancer